Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tacrolimus

FDA-approved product (capsule, oral), marketed as Astagraf Xl, Envarsus Xr, Prograf and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Tacrolimus
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atopic eczema
  • Delayed Graft Function
  • Eczematoid dermatitis
  • Immune system disease
  • Kidney transplant
  • Liver transplant

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Agents for dermatitis, excluding corticosteroids; Calcineurin inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae44.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tacrolimus in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tacrolimus with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AML

    NCT07572695 · start 2026-04-30

    Registered record
    Registry ID
    NCT07572695
    Conditions
    Acute Myeloid Leukemia; Relapsed/Refractory Acute Myeloid Leukemia; AML, Relapsed/Refractory
    Interventions
    Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (haplo-HSCT); Post-transplant Maintenance Therapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-04-30
    Completion
    2028-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Relapsed/Refractory Acute Myeloid Leukemia; AML, Relapsed/Refractory
    InterventionHaploidentical Allogeneic Hematopoietic Stem Cell Transplantation (haplo-HSCT); Post-transplant Maintenance Therapy
    PhaseNot recorded
    Registry statusNot yet recruiting

  • A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

    NCT07412470 · start 2026-03-13

    Registered record
    Registry ID
    NCT07412470
    Conditions
    Kidney Transplant Rejection
    Interventions
    Frexalimab; Frexalimab; Tacrolimus; rabbit anti-thymocyte globulin; mycophenolate mofetil; mycophenolate sodium; methylprednisolone; prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2026-03-13
    Completion
    2033-08-15
    Enrolment
    526

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Transplant Rejection
    InterventionFrexalimab; Frexalimab; Tacrolimus; rabbit anti-thymocyte globulin +4 more
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Safety and Efficacy Study of Absorbable Tacrolimus Lacrimal Canalicular Plug for Dry Eye

    NCT07806240 · start 2025-04-08

    Registered record
    Registry ID
    NCT07806240
    Conditions
    Dry Eye Disease (DED)
    Interventions
    Absorbable tacrolimus lacrimal canalicular plug; Dissolvable VisiPlug
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2025-04-08
    Completion
    2026-02-28
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye Disease (DED)
    InterventionAbsorbable tacrolimus lacrimal canalicular plug; Dissolvable VisiPlug
    PhaseNot applicable
    Registry statusCompleted

  • Phase 2 Study of Rapcabtagene Autoleucel in Myositis

    NCT06665256 · start 2024-12-17

    Registered record
    Registry ID
    NCT06665256
    Conditions
    Idiopathic Inflammatory Myopathies
    Interventions
    Rapcabtagene autoleucel; Active Comparator Option
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2024-12-17
    Completion
    2032-11-29
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Inflammatory Myopathies
    InterventionRapcabtagene autoleucel; Active Comparator Option
    PhasePhase 2
    Registry statusActive not recruiting

  • Low-dose Cyclophosphamide or CNI in the Prevention of Acute Graft-versus-host Disease After gDLI

    NCT06490562 · start 2024-07

    Registered record
    Registry ID
    NCT06490562
    Conditions
    Acute Graft-versus-host Disease
    Interventions
    PDCy; Non Cy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2024-07
    Completion
    2028-12
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Graft-versus-host Disease
    InterventionPDCy; Non Cy
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Use of Belatacept to Delay Tacrolimus Initiation in Kidney Transplant Patients With Delayed Graft Function

    NCT06091995 · start 2022-08-22

    Registered record
    Registry ID
    NCT06091995
    Conditions
    Use of Belatacept in Kidney Transplant Patients
    Interventions
    impact of administering one dose of belatacept on Estimated Glomerular Filtration Rate(eGFR)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-08-22
    Completion
    2025-07-07
    Enrolment
    67

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUse of Belatacept in Kidney Transplant Patients
    Interventionimpact of administering one dose of belatacept on Estimated Glomerular Filtration Rate(eGFR)
    PhaseNot recorded
    Registry statusCompleted

  • Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

    NCT04177004 · start 2021-04-30

    Registered record
    Registry ID
    NCT04177004
    Conditions
    Allogeneic Hematopoietic Stem Cell Transplant Recipient; Hematopoietic and Lymphoid Cell Neoplasm
    Interventions
    Allogeneic Hematopoietic Stem Cell Transplantation; Cyclophosphamide; Etoposide; Fractionated Stereotactic Radiation Therapy; Goat Milk; Palifermin; Sirolimus; Tacrolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2021-04-30
    Completion
    2026-10-27
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllogeneic Hematopoietic Stem Cell Transplant Recipient; Hematopoietic and Lymphoid Cell Neoplasm
    InterventionAllogeneic Hematopoietic Stem Cell Transplantation; Cyclophosphamide; Etoposide; Fractionated Stereotactic Radiation Therapy +4 more
    PhasePhase 1
    Registry statusActive not recruiting

  • Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients

    NCT04701528 · start 2020-11-15

    Registered record
    Registry ID
    NCT04701528
    Conditions
    Covid19; Kidney Transplant Infection
    Interventions
    Voclosporin; Tacrolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-11-15
    Completion
    2022-10-25
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19; Kidney Transplant Infection
    InterventionVoclosporin; Tacrolimus
    PhasePhase 2
    Registry statusCompleted

  • Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)

    NCT04646356 · start 2020-10-20

    Registered record
    Registry ID
    NCT04646356
    Conditions
    Hereditary Hemorrhagic Telangiectasia; Epistaxis Nosebleed
    Interventions
    Tacrolimus capsule (low-dose)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-10-20
    Completion
    2024-10-21
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHereditary Hemorrhagic Telangiectasia; Epistaxis Nosebleed
    InterventionTacrolimus capsule (low-dose)
    PhasePhase 2
    Registry statusCompleted

  • Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention

    NCT04503616 · start 2020-09-16

    Registered record
    Registry ID
    NCT04503616
    Conditions
    Graft-versus-host Disease
    Interventions
    Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2020-09-16
    Completion
    2024-08-15
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGraft-versus-host Disease
    InterventionCyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

    NCT04498741 · start 2020-07-08

    Registered record
    Registry ID
    NCT04498741
    Conditions
    RSV Infection
    Interventions
    EDP-938; EDP-938; EDP-938; Tacrolimus; Dabigatran; Rosuvastatin; EDP-938; Midazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-07-08
    Completion
    2021-06-01
    Enrolment
    89

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRSV Infection
    InterventionEDP-938; EDP-938; EDP-938; Tacrolimus +4 more
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety of Once-Daily Tacrolimus in Liver Transplant Recipients (SOUL)

    NCT04069065 · start 2019-07-31

    Registered record
    Registry ID
    NCT04069065
    Conditions
    Liver Transplant
    Interventions
    Conversion to Once-daily Tacrolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-07-31
    Completion
    2021-04-08
    Enrolment
    146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplant
    InterventionConversion to Once-daily Tacrolimus
    PhasePhase 4
    Registry statusUnknown

  • Comparison of Lindioil (Indigo Naturalis Oil Extract) Ointment to Protopic® Ointment 0.1% in Treating Atopic Dermatitis

    NCT03614221 · start 2019-06-03

    Registered record
    Registry ID
    NCT03614221
    Conditions
    Atopic Dermatitis
    Interventions
    Lindioil ointment; Protopic ointment 0.1%
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-06-03
    Completion
    2021-12-06
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionLindioil ointment; Protopic ointment 0.1%
    PhasePhase 2
    Registry statusCompleted

  • UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia

    NCT03913026 · start 2019-04-01

    Registered record
    Registry ID
    NCT03913026
    Conditions
    High Risk Hematologic Malignancy; Cord Blood Transplant
    Interventions
    Transplant with an expanded ECT-001 cord blood
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-04-01
    Completion
    2027-06
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh Risk Hematologic Malignancy; Cord Blood Transplant
    InterventionTransplant with an expanded ECT-001 cord blood
    PhasePhase 2
    Registry statusActive not recruiting

  • Evaluation of the Impact of Tacrolimus-based Immunosuppression on Heidelberg Liver Transplant Cohort (HDTACRO): Study Protocol for an Investigator Initiated, Non-interventional Prospective Study

    NCT04444817 · start 2018-11-22

    Registered record
    Registry ID
    NCT04444817
    Conditions
    Liver Transplantation
    Interventions
    Tacrolimus
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-11-22
    Completion
    2021-12-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplantation
    InterventionTacrolimus
    PhaseNot recorded
    Registry statusUnknown